Literature DB >> 9881536

The costs of depression: direct and indirect; treatment versus nontreatment.

P J Panzarino1.   

Abstract

Depression is one of the most costly illnesses in the United States today. While managed care often focuses on the costs of treatment, the costs of nontreatment are usually ignored. We have potent treatments that are highly successful, but depression is often undetected or undertreated where it appears most commonly-in the primary care setting. When comorbid with other medical problems, especially cardiovascular disease, depression greatly increases mortality, morbidity, and expense. Sophisticated pharmacoeconomic analyses can guide our cost/benefit studies, but the real cost savings and highest quality care will come by investing in educating primary care physicians regarding the recognition and treatment of psychiatric illness as it presents in their clinical practices.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9881536

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  [Are bonus systems applicable to guideline-oriented depression treatment provided by general practitioners and neurologists?].

Authors:  F Schneider; R Menke; M Härter; H J Salize; B Janssen; F Bergmann; M Berger; W Gaebel
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

Review 2.  Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment.

Authors:  Julie M Donohue; Harold Alan Pincus
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Long-term patterns of depression and associations with health and function in a panel study of rheumatoid arthritis.

Authors:  Anne Morris; Edward H Yelin; Pantelis Panopalis; Laura Julian; Patricia P Katz
Journal:  J Health Psychol       Date:  2011-03-18

4.  Association of Baseline Sleep Quality With Trajectories of Depressive Symptoms in Patients Undergoing Interferon Treatment.

Authors:  Megan M Marron; Stewart J Anderson; Jessica Garrity; Charles F Reynolds; Francis E Lotrich
Journal:  Psychosom Med       Date:  2015-10       Impact factor: 4.312

5.  The impact of parity on major depression treatment quality in the Federal Employees' Health Benefits Program after parity implementation.

Authors:  Alisa B Busch; Haiden A Huskamp; Sharon-Lise T Normand; Alexander S Young; Howard Goldman; Richard G Frank
Journal:  Med Care       Date:  2006-06       Impact factor: 2.983

6.  Polyunsaturated fatty acids moderate the effect of poor sleep on depression risk.

Authors:  Francis E Lotrich; Barry Sears; Robert K McNamara
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2015-11-10       Impact factor: 4.006

7.  Combined Use of Opioids and Antidepressants in the Treatment of Pain: A Review of Veterans Health Administration Data for Patients with Pain Both With and Without Co-morbid Depression.

Authors:  John J Sellinger; Mehmet Sofuoglu; Robert D Kerns; Robert A Rosenheck
Journal:  Psychiatr Q       Date:  2016-12

8.  Cost-effectiveness of collaborative care for chronically ill patients with comorbid depressive disorder in the general hospital setting, a randomised controlled trial.

Authors:  Eva K Horn; Tjeerd B van Benthem; Leona Hakkaart-van Roijen; Harm W J van Marwijk; Aartjan T F Beekman; Frans F Rutten; Christina M van der Feltz-Cornelis
Journal:  BMC Health Serv Res       Date:  2007-02-26       Impact factor: 2.655

9.  Cost-Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective.

Authors:  Andrea Carta; Maria Del Zompo; Anna Meloni; Francesco Mola; Pasquale Paribello; Federica Pinna; Marco Pinna; Claudia Pisanu; Mirko Manchia; Alessio Squassina; Bernardo Carpiniello; Claudio Conversano
Journal:  Clin Drug Investig       Date:  2022-08-05       Impact factor: 3.580

10.  Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature - 2001-2007.

Authors:  Christine Y Lu; Dennis Ross-Degnan; Stephen B Soumerai; Sallie-Anne Pearson
Journal:  BMC Health Serv Res       Date:  2008-04-07       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.